OBJECTIVES: To evaluate the utility of dielectric blood coagulometry for early sepsis–induced disseminated intravascular coagulation diagnosis.

DESIGN: Single-center, prospective observational study.

SETTING: Patients with sepsis or septic shock at the Tokyo Medical and Dental University Hospital of Medicine between September 2019 and September 2020.

PATIENTS: The patients were divided into three groups according to the timing of disseminated intravascular coagulation diagnosis based on the Disseminated Intravascular Coagulation score by the Japanese Association for Acute Medicine: 1) no disseminated intravascular coagulation group, 2) late-diagnosed disseminated intravascular coagulation group: not diagnosed with disseminated intravascular coagulation on day 1 but diagnosed within 48 hours after admission, and 3) disseminated intravascular coagulation group: diagnosed with disseminated intravascular coagulation on day 1. The study evaluated 80 patients (no disseminated intravascular coagulation, 31 [38.8%]; late-diagnosed disseminated intravascular coagulation, 34 [42.5%]; disseminated intravascular coagulation, 15 [18.8%]).

MEASUREMENTS AND MAIN RESULTS: We compared the clinical severity scores and mortality of the groups and assessed the correlation between the dielectric blood coagulometry–derived coagulation marker, thrombin levels, and Disseminated Intravascular Coagulation score using Spearman rank correlation. The mortality rate was 0% (0/31) in the no disseminated intravascular coagulation group, 35.3% (12/34) in the late-diagnosed disseminated intravascular coagulation group, and 33.3% (5/15) in the disseminated intravascular coagulation group. Although the Disseminated Intravascular Coagulation score on day 1 did not reflect disseminated intravascular coagulation in approximately 70% of patients who developed disseminated intravascular coagulation by day 2, dielectric clot strength measured by dielectric blood coagulometry on day 1 strongly correlated with disseminated intravascular coagulation development by day 2 (Spearman $\rho = 0.824; p < 0.05$) and with thrombin level on day 1 (Spearman $\rho = 0.844; p < 0.05$).

CONCLUSIONS: Dielectric blood coagulometry can be used to detect early-phase disseminated intravascular coagulation in patients with sepsis and is strongly correlated with thrombin levels. Larger studies are needed to verify our results for developing clinical applications.

KEY WORDS: dielectric blood coagulometry; disseminated dysfunction of blood coagulation; sepsis; thrombin

Sepsis, defined as organ dysfunction caused by a dysregulated host response to infection, is a life-threatening condition (1). Disseminated intravascular coagulation (DIC) is often considered one of such organ dysfunctions,
and it is common in sepsis and strongly associated with mortality (2, 3). In DIC, the activation of coagulation via the elevation of thrombin levels is initiated by the expression of tissue factors on activated monocytes and endothelial cells, which results in microvascular thrombosis leading to tissue ischemia and multiple organ dysfunctions (4). The early recognition and treatment of DIC would prevent significant complications (2).

Thrombin is a protein involved in the early regulation of coagulation and hemostatic processes (5), and excessive thrombin production is one of the major characteristics of DIC. Although thrombin levels increase 3–5 hours after the occurrence of bacteremia or endotoxemia, it is inhibited rapidly by antithrombin as a biological defense reaction against the DIC (6, 7). Therefore, although measuring pure soluble thrombin levels is ideal for real-time coagulation monitoring, it is not practical in clinical settings because most measuring assays are costly, highly complex, and time consuming (8). Clinically, DIC is diagnosed using scoring systems proposed by several organizations (9, 10). However, early detection is often challenging because of the time lag between DIC development and the elevation of the scores. Furthermore, the relationship between these scoring systems and thrombin level has not been fully elucidated.

Recently, dielectric blood coagulometry (DBCM) was developed to evaluate blood coagulability by measuring the change in the dielectric permittivity of the whole blood sample. To date, there have been several reports about DBCM in various fields, including the prediction of thrombosis (11) and stroke (12). We hypothesized that coagulation measurements by DBCM would enable the detection of the early phase of DIC and reflect thrombin levels more accurately than existing diagnostic scores. The purpose of this study was to assess the utility of DBCM in recognizing the early phase of DIC and predict thrombin levels.

MATERIALS AND METHODS

Design, Setting, and Ethics Approval

This study was a prospective observational study and included patients with sepsis or septic shock admitted at the Tokyo Medical and Dental University Hospital of Medicine, a Japanese tertiary critical care center, between September 2019 and September 2020. This study complied with the principles of the 1964 Declaration of Helsinki and its later amendments. The study was approved by the institutional review board of Tokyo Medical and Dental University (number 2018-320). Written informed consent was obtained from the patients or their relatives at the time of hospital admission.

Study Population

Patients diagnosed with sepsis or septic shock based on the Sepsis-3 criteria upon admission at the emergency department (ED) were prospectively enrolled (13). Patients who met at least one of the following criteria were excluded from the analysis: 1) age less than 18 years, 2) had do-not-attempt-resuscitation orders, 3) received cardiopulmonary resuscitation before admission, 4) transferred from another hospital, 5) transferred to another hospital within 24 hours after admission, 6) history of malignancy, and 7) missing or insufficient data regarding the study variables. In addition, patients were excluded if they had a history of anticoagulant or antiplatelet medication because these agents could significantly affect clotting function. All included patients received treatments according to the Surviving Sepsis Campaign guideline 2016 (14).

Data Collection

The following information was collected prospectively: age; sex; Charlson Comorbidity Index (15); the primary source of infection; concomitant therapies; the Acute Physiology and Chronic Health Evaluation II score and the Sequential Organ Failure Assessment score on days 1, 2, and 3; ventilator-free days (VFDs) (16); ICU-free days (IFDs) at 28 days (17); and status at hospital discharge (i.e., dead or alive).

Blood Collection and Laboratory Analysis

The first blood sampling was performed as soon as possible upon arrival at the ED (day 1) to eliminate the effect of any therapeutic interventions. Blood samples were also collected on days 2 and 3. Whole blood was analyzed using DBCM immediately after the blood collection. In addition, platelet-poor plasma (PPP) was immediately processed from the remaining whole blood by consecutive centrifugations (2,500g for 15 min at 4°C) and stored at –80°C. The soluble thrombin level in the PPP was measured by enzyme-linked immunosorbent assay (ELISA) immediately after thawing the
frozen sample at room temperature to minimize the in vitro effect of proteases converting prothrombin to thrombin, using antibodies against human thrombin (Human Thrombin ELISA Kit [Factor II], ab108909; Abcam, Cambridge, United Kingdom). This antibody was designed for the quantitative measurement of the pure soluble thrombin concentrations (i.e., independent from thrombin-antithrombin complex), and the measurable range was 0.31–20.0 ng/mL. Regarding standard laboratory data, complete blood count was measured using an XN-9000 auto-analyzer (Sysmex Corporation, Kobe, Japan), and prothrombin time and fibrin/fibrinogen degradation product were measured by a CS-5100 auto-analyzer (Sysmex Corporation).

**DBCM Analysis**

To measure the coagulation status, DBCM analyses were performed on days 1–3 with a dielectric coagulometer (Sony Corp., Tokyo, Japan) (18), approved for clinical use in Japan in September 2019 (Supplementary Fig. 1, http://links.lww.com/CCM/G629; legend, http://links.lww.com/CCM/G634). The main response to DBCM is produced by the aggregation and shape transformation of erythrocytes during coagulation (18). The DBCM uses dielectric spectroscopy to measure blood rheology. Each cell in the whole blood, including the erythrocytes, could be considered as a component of an electrical circuit. When whole blood is applied to the reagent cartridge and placed into the alternating current electric field, the dielectric constant spectrum changes according to the aggregation and shape transformation of erythrocytes during coagulation (18). During this process, the dielectric clot strength (DCS), a variable of fibrin formation, can be estimated by measuring and analyzing changes in permittivity associated with blood coagulation with high sensitivity. The reference range of the DCS calculated by DBCM is 17–29. The DCS is not significantly affected by the blood cell counts, coagulation factors, electrolytes, or blood temperature. However, severe polycythemia and/or anemia could affect the result; DCS can be measured appropriately when the hematocrit is in the range of 20–60%.

**Score-Based DIC Diagnosis**

The DIC score was calculated on days 1–3 based on the Japanese Association for Acute Medicine (JAAM) criteria (10) (Supplementary Table 1, http://links.lww.com/CCM/G630), which is widely used in Japan (19). The diagnosis of DIC was confirmed if the JAAM score was 4 points or higher.

Based on the timing of DIC diagnosis, the patients were divided into three groups: 1) no-DIC; 2) late-diagnosed DIC, which included patients who were not diagnosed with DIC upon ED admission but were diagnosed with DIC during the first 48 hours after admission using the JAAM criteria; and 3) DIC, which comprised patients who were diagnosed with DIC upon ED admission using the JAAM criteria.

**Statistical Analysis**

We evaluated the differences between the aforementioned three groups with regard to the clinical scores and laboratory results. In the univariate analysis, continuous variables were compared using the Student t test or Mann-Whitney U test. Categorical variables were compared using the chi-square test or Fisher exact test, depending on the distribution. First, we used a one-way analysis of variance (ANOVA) to assess the differences between the three groups. Thereafter, we performed a post hoc residual analysis to identify the divergent group when a significant difference was observed in the one-way ANOVA. The residual was the difference between the observed value and the mean of all the expected values within each group. A significant adjusted standardized residual indicated a significant difference in the corresponding variable. In this analysis, Bonferroni correction was used to address multiple comparisons. The correlation between DCS calculated by DBCM, the JAAM DIC score, and thrombin levels in PPP was evaluated using a Spearman rank correlation test. Furthermore, we explored the correlation between each variable in the JAAM DIC score and the DCS on each day. All statistical analyses were conducted using R software (Version 3.4.3; R Foundation for Statistical Computing, Vienna, Austria). Two-sided p values less than 0.05 were considered statistically significant.

**RESULTS**

Figure 1 shows the patient selection diagram. Among 101 potentially eligible patients, we analyzed 80; among them, 31 patients (38.8%), 34 patients (42.5%), and 15 patients (18.8%) were assigned to the no-DIC,
late-diagnosed DIC, and DIC groups, respectively. Table 1 presents the characteristics of the groups. All patients in the late-diagnosed DIC group were diagnosed with DIC within 2 days after admission. No significant differences were observed regarding the patient demographics and primary source of infection. Compared with the no-DIC group, the late-diagnosed DIC and DIC groups had higher severity scores on all the days. Patients who developed DIC, including late-diagnosed DIC, were likely to undergo invasive treatments and received larger amounts of fluid and anticoagulation therapy.

Table 2 shows a comparison of the outcomes. The mortality rate in the no-DIC group was 0% (0/31), 35.3% (12/34) in the late-diagnosed DIC group, and 33.3% (5/15) in the DIC group. Similarly, the thrombin levels in the late-diagnosed DIC and DIC groups were significantly higher on day 1 than in the no-DIC group (median [interquartile range], 2.3 [1.8–2.9] vs 5.8 [4.3–6.9] vs 6.6 [5.5–7.4]; p < 0.001). The correlation between the JAAM DIC score, DCS level, and thrombin level in the three groups are summarized in Table 3. The late-diagnosed DIC and DIC groups had significantly higher DCS levels on day 1 than the no-DIC group (median [interquartile range], 22.8 [18.2–28.4] in the no-DIC group vs 51.9 [43.3–56.1] in the late-diagnosed DIC group vs 53.3 [47.4–57.5] in the DIC group; p < 0.001). Similarly, the thrombin levels in the late-diagnosed DIC and DIC groups were significantly higher on day 1 than in the no-DIC group (median [interquartile range], 2.3 [1.8–2.9] vs 5.8 [4.3–6.9] vs 6.6 [5.5–7.4]; p < 0.001). The correlation between the JAAM DIC score, DCS level, and thrombin level is shown in Table 4. The DCS level on day 1 was strongly correlated with thrombin level on day 1 (ρ = 0.844; p < 0.05) and DIC score on day 2 (ρ = 0.824; p < 0.05). However, we did not observe a correlation between the DCS level on day 1 and the DIC score on day 1 (ρ = 0.384; p = 0.081). Similarly, thrombin level on day 1 was strongly correlated with the DIC score on day 2 (ρ = 0.801; p < 0.05) and weakly correlated with the DIC score on day 1 (ρ = 0.364; p < 0.05). The individual variables of the JAAM DIC score according to group are summarized in Supplementary Table 3 (http://links.lww.com/CCM/G632). We did not observe strong correlations between individual variables of the JAAM DIC score and DCS level (Supplementary Table 4, http://links.lww.com/CCM/G633).

**DISCUSSION**

In this prospective observational study, we evaluated the utility of DBCM for the early detection of DIC and thrombin level in 80 patients with sepsis. The main findings were as follows: 1) the severity and mortality of patients with a delayed diagnosis were similar to those of patients who were diagnosed with DIC upon ED admission and higher than those of patients who...
did not develop DIC; 2) the JAAM criteria failed to diagnose the early phase of DIC on day 1, as approximately 70% of patients who developed DIC were not identified; and 3) the DCS level estimated by DBCM on day 1 could detect late-diagnosed DIC and DIC upon hospital admission and was strongly correlated with the thrombin level on day 1. To the best of our knowledge, this is the first study to evaluate the association

### TABLE 1.
Comparison of the Characteristics of Patients

| Variable                          | No-DIC Group (N = 31) | Late-Diagnosed DIC Group (N = 34) | DIC Group (N = 15) | p   |
|-----------------------------------|-----------------------|-----------------------------------|--------------------|-----|
| **Baseline characteristic**       |                       |                                   |                    |     |
| Age (yr), median (interquartile range) | 71 (63–88)           | 74 (50–89)                        | 77 (74–86)         | 0.466|
| Male, n (%)                       | 23 (74.2)             | 21 (62.0)                         | 11 (73.3)          | 0.878|
| Charlson Comorbidity Index score, median (interquartile range) | 3 (3–4)               | 3 (2–4)                           | 3 (2–4)            | 0.453|
| **Site of infection, n (%)**      |                       |                                   |                    |     |
| Lung                              | 8 (25.8)              | 6 (17.6)                          | 3 (20.0)           | 0.224|
| Abdominal                         | 5 (16.1)              | 9 (26.5)                          | 5 (33.3)           | 0.142|
| Urinary                           | 6 (19.3)              | 11 (32.4)                         | 5 (33.3)           | 0.129|
| Soft tissue                       | 8 (25.8)              | 4 (11.8)                          | 1 (6.7)            | 0.078|
| Other or unknown                  | 4 (12.9)              | 4 (11.8)                          | 1 (6.7)            | 0.243|
| **Severity scores**               |                       |                                   |                    |     |
| Sequential Organ Failure Assessment score, median (interquartile range) |                       |                                   |                    |     |
| Day 1                             | 3 (2–6)               | 7 (3–15)                          | 11 (8–16)          | < 0.001|
| Day 2                             | 4 (2–8)               | 15 (10–16)                        | 16 (9–19)          | < 0.001|
| Day 3                             | 2 (1–4)               | 15 (8–19)                         | 12 (8–16)          | < 0.001|
| Acute Physiology and Chronic Health Evaluation II score, median (interquartile range) |                       |                                   |                    |     |
| Day 1                             | 3 (2–8)               | 11 (3–16)                         | 13 (6–19)          | < 0.001|
| Day 2                             | 5 (3–8)               | 17 (10–21)                        | 15 (7–18)          | < 0.001|
| Day 3                             | 5 (4–7)               | 15 (7–19)                         | 14 (8–18)          | < 0.001|
| **Therapy**                       |                       |                                   |                    |     |
| Total infusion volume within first 3 d (mL/kg), median (interquartile range) | 72 (66–79)            | 88 (78–95)                        | 91 (80–96)         | < 0.001|
| Platelet concentrates, n (%)      | 0 (0.0)               | 9 (26.4)                          | 5 (33.3)           | < 0.001|
| Albumin, n (%)                    | 1 (3.2)               | 9 (26.4)                          | 7 (46.7)           | < 0.001|
| Surgery, n (%)                    | 0 (0.0)               | 4 (11.8)                          | 6 (40.0)           | < 0.001|
| Renal replacement therapy, n (%)  | 2 (6.5)               | 8 (23.5)                          | 7 (46.7)           | 0.003|
| Mechanical ventilation, n (%)     | 2 (6.5)               | 17 (50.0)                         | 8 (53.3)           | < 0.001|
| Extracorporeal life support, n (%)| 0 (0.0)               | 0 (0.0)                           | 0 (0.0)            | 1.000|
| Anticoagulants, n (%)             |                       |                                   |                    |     |
| Recombinant thrombomodulin        | 0 (0.0)               | 2 (5.9)                           | 1 (6.7)            | 0.314|
| Antithrombin concentrates         | 1 (3.2)               | 8 (23.5)                          | 5 (33.3)           | 0.003|
| Heparin                           | 2 (6.5)               | 5 (14.7)                          | 3 (20.0)           | 0.196|

DIC = disseminated intravascular coagulation.

We used one-way analysis of variance to assess the differences between the three groups.

Critical Care Medicine  www.ccmjournal.org  e35
among a DBCM-derived variable, thrombin level, and DIC score.

Several guidelines for the diagnosis and treatment of DIC have been reported (20–22). The JAAM criteria were published in 2006 for DIC diagnosis (23), and they have shown higher sensitivity and predictive accuracy compared with other DIC criteria (10, 24). However, the present study showed that the JAAM criteria were not sensitive enough to diagnose the early phase of DIC. Recent studies have shown that early anticoagulation therapy might be beneficial in a specific subpopulation with sepsis-induced DIC (25, 26), suggesting that the delay of diagnosis could worsen patient outcomes. Our results indicate that DBCM could help clinicians detecting the early phase of DIC in patients with sepsis at a high risk of death.

### TABLE 2.
Comparison of the Outcomes

| Outcomes                        | No-DIC Group ($N = 31$) | Late-Diagnosed DIC Group ($N = 34$) | DIC Group ($N = 15$) | $p$   |
|---------------------------------|-------------------------|-------------------------------------|----------------------|-------|
| In-hospital mortality, n (%)    | 0 (0)                   | 12 (35.3)                           | 5 (33.3)             | < 0.001|
| Ventilator-free days (d), median (interquartile range) | 28 (28–28)          | 18 (15–25)                           | 19 (17–24)           | < 0.001|
| ICU-free days (d), median (interquartile range)  | 25 (24–27)          | 12 (3–17)                            | 14 (5–18)            | < 0.001|

DIC = disseminated intravascular coagulation.
One-way analysis of variance was used to estimate the $p$ value.

### TABLE 3.
Japanese Association for Acute Medicine 2006 Disseminated Intravascular Coagulation Score, Dielectric Clot Strength Level, and Thrombin Level in the Three Groups According to Disseminated Intravascular Coagulation Development

| Variable                                           | No-DIC Group ($N = 31$) | Late-Diagnosed DIC Group ($N = 34$) | DIC Group ($N = 15$) | $p$   |
|-----------------------------------------------------|-------------------------|-------------------------------------|----------------------|-------|
| Japanese Association for Acute Medicine 2006 DIC score, median (interquartile range) |                           |                                     |                      |       |
| Day 1                                               | 2.1 (1.7–2.3)           | 2.2 (1.6–3.0)                       | 5.2 (4.1–6.0)        | < 0.001|
| Day 2                                               | 1.9 (1.8–2.2)           | 5.4 (4.6–6.0)                       | 5.8 (4.1–7.0)        | < 0.001|
| Day 3                                               | 2.0 (1.4–2.5)           | 6.5 (4.9–7.5)                       | 6.2 (4.5–7.1)        | < 0.001|
| Laboratory results, median (interquartile range)    |                           |                                     |                      |       |
| Dielectric clot strength level measured by dielectric blood coagulometry |                           |                                     |                      |       |
| Day 1                                               | 22.8 (18.2–28.4)        | 51.9 (43.3–56.1)                    | 53.3 (47.4–57.5)     | < 0.001|
| Day 2                                               | 19.2 (15.8–24.1)        | 33.0 (24.3–38.3)                    | 31.2 (26.1–40.5)     | 0.072 |
| Day 3                                               | 21.5 (14.8–23.4)        | 31.0 (27.3–34.3)                    | 29.2 (25.1–34.5)     | 0.132 |
| Thrombin level                                       |                           |                                     |                      |       |
| Day 1 (ng/mL)                                       | 2.3 (1.8–2.9)           | 5.8 (4.3–6.9)                       | 6.6 (5.5–7.4)        | < 0.001|
| Day 2 (ng/mL)                                       | 2.2 (1.1–2.8)           | 3.3 (2.4–3.6)                       | 3.2 (2.3–3.9)        | 0.103 |
| Day 3 (ng/mL)                                       | 1.8 (1.0–2.8)           | 2.8 (1.9–3.3)                       | 2.9 (2.3–3.5)        | 0.214 |

DIC = disseminated intravascular coagulation.
One-way analysis of variance was used to estimate the $p$ value.
assesses fibrin clot formation in general, the measurement of thrombin generation could provide more information on the total coagulation capacity (29). However, because thrombin has a short half-life and is rapidly bound by naturally occurring inhibitors, the real-time measurement of thrombin level is difficult in clinical settings (30, 31). Our results indicate that DCS estimated by DBCM could be an alternative to measure thrombin level in patients with sepsis.

Most coagulation markers, to calculate DIC scores, do not use whole blood but plasma. Thus, information on blood cells, which play a critical role in the coagulation process, is lacking in these conventional measurement methods (32). DBCM can evaluate whole blood dielectric permittivity by detecting the aggregation and deformation of RBCs associated with early fibrin formation (19). Excessive thrombin generation, which can cause impaired fibrin degradation leading to intravascular fibrin deposition, is characteristic of DIC (33, 34). These interactions between plasma factors and blood cells would partially explain why DBCM could detect coagulation abnormalities related to thrombin generation and fibrin formation in the early phase of DIC. However, detailed interactions in the process of clotting have not been elucidated when DBCM is used to estimate coagulation status. Further investigation is required to clarify the mechanism underlying the abnormal coagulation function that affects DBCM variables.

Several limitations should be considered when interpreting the results of our study. First, this was an observational study conducted at a single center, which prevented us from performing statistical adjustments for potential confounders due to the limited sample size. Additional research is necessary to provide more definitive data, including large-scale studies adjusted by covariates. Second, we did not consider the effects of treatment, including anticoagulation and fluid therapy, which could influence the coagulation state and DIC score on days 2 and 3. Although there were no patients with severe polycythemia and/or anemia at hospital admission, fluid therapy could cause blood dilution and may affect the results. Third, in the thrombin assay, any protease inhibitors were not used to stop conversion from prothrombin to thrombin. Furthermore, although an ideal PPP processing protocol had not been established, cold activation of Factor VII (35) remained in the centrifugation process to prepare the PPP at low temperatures. These factors could have affected the thrombin concentrations. Fourth, a comparison between DBCM and specific modalities for monitoring global blood coagulability, such as thromboelastography or rotational thromboelastometry (ROTEM), was not performed in this study (36–38). Further research is needed to compare DBCM and thromboelastography/ROTEM results and assess their utility for predicting DIC development. Despite these limitations,
our study highlights the utility of DBCM in the early recognition of DIC and thrombin levels in patients with sepsis. These findings provide relevant insight into the diagnosis and treatment strategies for sepsis-induced DIC.

CONCLUSIONS

DCS measured by DBCM was used to detect the early phase of sepsis-induced DIC and was correlated with thrombin levels. This procedure could lead to the accurate and swift diagnosis and timely treatment of early sepsis-induced DIC. Larger studies are necessary to investigate the generalizability of our results and the feasibility of a clinical application.

ACKNOWLEDGMENTS

We thank all the enrolled patients and their families, physicians, nurses, paramedics, and all staff. Furthermore, we thank Yoshihito Hayashi (Medical Business Unit, Sony Corporation, Tokyo Medical and Dental University) for his feedback on the article.

1 Department of Acute Critical Care and Disaster Medicine, Graduate School of Tokyo Medical and Dental University, Tokyo Medical and Dental University, Tokyo, Japan.

2 Trauma and Acute Critical Care Center, Tokyo Medical and Dental University Hospital of Medicine, Tokyo, Japan.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (http://journals.lww.com/ccmj). Dr. Takayama received funding from the Japan Society for the Promotion of Science KAKENHI grant number T20K17854-0. The remaining authors have disclosed that they do not have any potential conflicts of interest.

For information regarding this article, E-mail: tak2accm@tmd.ac.jp

REFERENCES

1. Martin GS, Mannino DM, Eaton S, et al: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546–1554
2. Reinhart K, Daniels R, Kissoon N, et al: Recognizing sepsis as a global health priority - a WHO resolution. N Engl J Med 2017; 377:414–417
3. Lyons PG, Micek ST, Hampton N, et al: Sepsis-associated coagulopathy severity predicts hospital mortality. Crit Care Med 2018; 46:736–742
4. Levi M, van der Poll T: Coagulation and sepsis. Thromb Res 2017; 149:38–44
5. Lancé MD: A general review of major global coagulation assays: Thrombelastography, thrombin generation test and clot waveform analysis. Thromb J 2015; 13:1
6. Boral BM, Williams DJ, Boral LI: Disseminated intravascular coagulation. Am J Clin Pathol 2016; 146:670–680
7. Rimpo K, Tanaka A, Ukai M, et al: Thrombin-antithrombin complex measurement using a point-of-care testing device for diagnosis of disseminated intravascular coagulation in dogs. PLoS One 2018; 13:e0205511
8. van Berkel SS, van der Lee B, van Delft FL, et al: Fluorogenic peptide-based substrates for monitoring thrombin activity. ChemMedChem 2012; 7:606–617
9. Taylor FB Jr, Toh CH, Hoots WK, et al; Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH): Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86:1327–1330
10. Gando S, Iba T, Eguchi Y, et al; Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC Study Group): A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: Comparing current criteria. Crit Care Med 2006; 34:625–631
11. Uchiyama H, Inoue Y, Uchimura I, et al: Prediction of venous thromboembolism after total knee arthroplasty using dielectric blood coagulometry. Ann Vasc Surg 2017; 38:286–292
12. Hasegawa Y, Hamada S, Nishimura T, et al: Novel dielectric coagulometer identifies hypercoagulability in patients with a high CHADS2 score without atrial fibrillation. PLoS One 2016; 11:e0156557
13. Singer M, Deutschman CS, Seymour CW, et al: The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 2016; 315:801–810
14. Rhodes A, Evans LE, Alhazzani W, et al: Surviving sepsis campaign: International guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 2017; 43:304–377
15. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987; 40:373–383
16. Schoenfeld DA, Bernard GR; ARDS Network: Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome. Crit Care Med 2002; 30:1772–1777
17. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network; Wiedemann HP, Wheeler AP, Goodman RB, et al: Comparison of two uid-management strategies in acute lung injury. N Engl J Med 2006; 354:2564–2575
18. Hayashi Y, Brun MA, Machida K, et al: Principles of dielectric blood coagulometry as a comprehensive coagulation test. Anal Chem 2015; 87:10072–10079
19. Nishida O, Ogura H, Egi M, et al; The Japanese clinical practice guidelines for management of sepsis and septic shock 2016 (J-SSCG 2016). Acute Med Surg 2018; 5:3–8
20. Wada H, Asakura H, Okamoto K, et al; Japanese Society of Thrombosis Hemostasis/DIC subcommittee: Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb Res 2010; 125:6–11
21. Di Nisio M, Baudo F, Cosmi B, et al; Italian Society for Thrombosis and Haemostasis: Diagnosis and treatment of disseminated intravascular coagulation: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res 2012; 129:e177–e184

22. Levi M, Toh CH, Thachil J, et al: Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol 2009; 145:24–33

23. Iba T, Thachil J: Present and future of anticoagulant therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation: A perspective from Japan. Int J Hematol 2016; 103:253–261

24. Gando S, Saitoh D, Ogura H, et al; Japanese Association for Acute Medicine Sepsis Registry Study Group: A multicenter, prospective validation study of the Japanese Association for Acute Medicine disseminated intravascular coagulation scoring system in patients with severe sepsis. Crit Care 2013; 17:R111

25. Umemura Y, Yamakawa K, Ogura H, et al: Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: A meta-analysis of randomized controlled trials. J Thromb Haemost 2016; 14:518–530

26. Yamakawa K, Umemura Y, Hayakawa M, et al; Japan Septic Disseminated Intravascular Coagulation (J-Septic DIC) study group: Benefit profile of anticoagulant therapy in sepsis: A nationwide multicentre registry in Japan. Crit Care 2016; 20:229

27. Tripodi A, Legnani C, Chantarangkul V, et al: High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. J Thromb Haemost 2008; 6:1327–1333

28. Hron G, Kollars M, Binder BR, et al: Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA 2006; 296:397–402

29. Hemker HC, Al Dieri R, De Smedt E, et al: Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost 2006; 96:553–561

30. Rühl H, Müller J, Harbrecht U, et al: Thrombin inhibition profiles in healthy individuals and thrombophilic patients. Thromb Haemost 2012; 107:848–853

31. Merlini PA, Ardissono D: Laboratory measurement of thrombin activity—what every clinician scientist needs to know. J Thromb Thrombolysis 1995; 2:85–92

32. Sasano T, Hasegawa Y, Hamada S: Novel measurements of blood coagulability for assessing the risk of thrombosis. Expert Rev Med Devices 2017; 14:321–323

33. Franchini M, Lippi G, Manzato F: Recent acquisitions in the pathophysiology, diagnosis and treatment of disseminated intravascular coagulation. Thromb J 2006; 4:4

34. Ralph AG, Brainard BM: Update on disseminated intravascular coagulation: When to consider it, when to expect it, when to treat it. Top Companion Anim Med 2012; 27:65–72

35. Seligsohn U, Zivelin A, Bar-Shani S: Cold-promoted activation of factor VII: Is it a problem under blood bank conditions? Haemostasis 1983; 13:186–191

36. Schöchl H, Nienaber U, Hofer G, et al: Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen concentrate and prothrombin complex concentrate. Crit Care 2010; 14:R55

37. Martini WZ, Cortez DS, Dubick MA, et al: Thrombelastography is better than PT, aPTT, and activated clotting time in detecting clinically relevant clotting abnormalities after hypothermia, hemorrhagic shock and resuscitation in pigs. J Trauma 2008; 65:535–543

38. Harr JN, Moore EE, Ghasabayan A, et al: Functional fibrinogen assay indicates that fibrinogen is critical in correcting abnormal clot strength following trauma. Shock 2013; 39:45–49